• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Critical care : >One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure
【24h】

One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure

机译：重症急性呼吸衰竭患者的一年死亡率，生活质量和预期的终身成本效用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionHigh daily intensive care unit (ICU) costs are associated with the use of mechanical ventilation (MV) to treat acute respiratory failure (ARF), and assessment of quality of life (QOL) after critical illness and cost-effectiveness analyses are warranted.MethodsNationwide, prospective multicentre observational study in 25 Finnish ICUs. During an eight-week study period 958 consecutive adult ICU patients were treated with ventilatory support over 6 hours. Of those 958, 619 (64.6%) survived one year, of whom 288 (46.5%) answered the quality of life questionnaire (EQ-5D). We calculated EQ-5D index and predicted lifetime quality-adjusted life years (QALYs) gained using the age- and sex-matched life expectancy for survivors after one year. For expired patients the exact lifetime was used. We divided all hospital costs for all ARF patients by the number of hospital survivors, and by all predicted lifetime QALYs. We also adjusted for those who died before one year and for those with missing QOL to be able to estimate the total QALYs.ResultsOne-year mortality was 35% (95% CI 32 to 38%). For the 288 respondents median [IQR] EQ-5D index after one year was lower than that of the age- and sex-matched general population 0.70 [0.45 to 0.89] vs. 0.84 [0.81 to 0.88]. For these 288, the mean (SD) predicted lifetime QALYs was 15.4 (13.3). After adjustment for missing QOL the mean predicted lifetime (SD) QALYs was 11.3 (13.0) for all the 958 ARF patients. The mean estimated costs were 20.739 € per hospital survivor, and mean predicted lifetime cost-utility for all ARF patients was 1391 € per QALY.ConclusionsDespite lower health-related QOL compared to reference values, our result suggests that cost per hospital survivor and lifetime cost-utility remain reasonable regardless of age, disease severity, and type or duration of ventilation support in patients with ARF.
机译：简介每天重症监护病房（ICU）的高成本与使用机械通气（MV）来治疗急性呼吸衰竭（ARF）有关，并且需要对严重疾病和成本效益分析后的生活质量（QOL）进行评估。 ，在25个芬兰ICU中进行的前瞻性多中心观察性研究。在为期八周的研究期内，连续958例成年ICU患者接受了6小时的通气支持。在958名患者中，有619名（64.6％）存活了一年，其中288名（46.5％）回答了生活质量问卷（EQ-5D）。我们计算了EQ-5D指数，并预测了使用一年后存活者的年龄和性别匹配的预期寿命而获得的终生质量调整生命年（QALYs）。对于过期的患者，使用确切的寿命。我们将所有ARF患者的所有医院费用除以幸存者的人数，再除以所有预期的终生QALY。我们还对一年前死亡的人和QOL缺失的人进行了调整，以能够估计总QALYs。结果一年死亡率为35％（95％CI为32至38％）。在288位受访者中，一年后的[IQR] EQ-5D中位数指数低于年龄和性别相匹配的普通人群，为0.70 [0.45至0.89]，而0.84 [0.81至0.88]。对于这288个样本，预测寿命QALY的平均值（SD）为15.4（13.3）。校正缺失的QOL后，所有958名ARF患者的平均预期寿命（SD）QALYs为11.3（13.0）。平均估计成本为每位幸存者20.739欧元，所有ARF患者的平均预期终生成本效用为每QALY 1391欧元。结论尽管与健康相关的QOL低于参考值，但我们的结果表明，每位幸存者的成本和终生成本无论年龄，疾病严重程度，ARF患者的通气支持类型或持续时间如何，均能保持合理的效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号